RU2157233C1 - Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения - Google Patents
Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения Download PDFInfo
- Publication number
- RU2157233C1 RU2157233C1 RU99108841/14A RU99108841A RU2157233C1 RU 2157233 C1 RU2157233 C1 RU 2157233C1 RU 99108841/14 A RU99108841/14 A RU 99108841/14A RU 99108841 A RU99108841 A RU 99108841A RU 2157233 C1 RU2157233 C1 RU 2157233C1
- Authority
- RU
- Russia
- Prior art keywords
- tetrapeptide
- glu
- asp
- ala
- gly
- Prior art date
Links
- 230000002398 geroprotective effect Effects 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000002831 pharmacologic agent Substances 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- -1 for example Chemical class 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 6
- 206010063493 Premature ageing Diseases 0.000 claims description 6
- 208000032038 Premature aging Diseases 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 239000011575 calcium Chemical class 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 150000001767 cationic compounds Chemical class 0.000 claims description 3
- 229910001411 inorganic cation Chemical class 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 150000002892 organic cations Chemical class 0.000 claims description 3
- 239000011591 potassium Chemical class 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical class CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Chemical class 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000011777 magnesium Chemical class 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 31
- 230000032683 aging Effects 0.000 abstract description 26
- 239000000126 substance Substances 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 230000000699 topical effect Effects 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 description 27
- 229940079593 drug Drugs 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 229960003987 melatonin Drugs 0.000 description 14
- 241000255601 Drosophila melanogaster Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 102000016938 Catalase Human genes 0.000 description 10
- 108010053835 Catalase Proteins 0.000 description 10
- 241000255925 Diptera Species 0.000 description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000006851 antioxidant defense Effects 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940009098 aspartate Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000004560 pineal gland Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000000607 neurosecretory system Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- RMZZTJOADJVCIO-UHFFFAOYSA-N acetic acid;acetonitrile;hydrate Chemical compound O.CC#N.CC(O)=O RMZZTJOADJVCIO-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940125384 geroprotector Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004258 Ethoxyquin Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- SAKUKAQFBMDKGX-UHFFFAOYSA-N butan-1-ol;2-pyridin-2-ylacetic acid;hydrate Chemical compound O.CCCCO.OC(=O)CC1=CC=CC=N1 SAKUKAQFBMDKGX-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019285 ethoxyquin Nutrition 0.000 description 2
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 2
- 229940093500 ethoxyquin Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- JMDKBDALNFZTOV-JQWIXIFHSA-N (2s)-2-[[(2s)-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 JMDKBDALNFZTOV-JQWIXIFHSA-N 0.000 description 1
- HGHOBRRUMWJWCU-FXQIFTODSA-N (4s)-4-[[(2s)-2-aminopropanoyl]amino]-5-[[(2s)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O HGHOBRRUMWJWCU-FXQIFTODSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical class CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- TYRGLVWXHJRKMT-UHFFFAOYSA-N 2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC(=O)C(C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-UHFFFAOYSA-N 0.000 description 1
- KZUIXWYHQJZUOK-UHFFFAOYSA-N 2-ethyl-6-methylpyridin-1-ium-3-ol;chloride Chemical compound Cl.CCC1=NC(C)=CC=C1O KZUIXWYHQJZUOK-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- 206010006440 Bronchial obstruction Diseases 0.000 description 1
- HGHOBRRUMWJWCU-UHFFFAOYSA-N CC(C(NC(CCC(O)=O)C(NC(CC(O)=O)C(NCC(O)=O)=O)=O)=O)N Chemical compound CC(C(NC(CCC(O)=O)C(NC(CC(O)=O)C(NCC(O)=O)=O)=O)=O)N HGHOBRRUMWJWCU-UHFFFAOYSA-N 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108700019186 Drosophila lin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020915 Hypervitaminosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- AOZUYISQWWJMJC-UHFFFAOYSA-N acetic acid;methanol;hydrate Chemical compound O.OC.CC(O)=O AOZUYISQWWJMJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007172 age related pathology Effects 0.000 description 1
- 108010084217 alanyl-glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WJKJXKRHMUXQSL-UHFFFAOYSA-N benzyl glycinate 4-methylbenzenesulfonate salt Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCC(=O)OCC1=CC=CC=C1 WJKJXKRHMUXQSL-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- KIZFHUJKFSNWKO-UHFFFAOYSA-M calcium monohydroxide Chemical compound [Ca]O KIZFHUJKFSNWKO-UHFFFAOYSA-M 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- UNYOJUYSNFGNDV-UHFFFAOYSA-M magnesium monohydroxide Chemical compound [Mg]O UNYOJUYSNFGNDV-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002613 pineal body hormone Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99108841/14A RU2157233C1 (ru) | 1999-05-11 | 1999-05-11 | Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения |
| AT00905499T ATE321068T1 (de) | 1999-05-11 | 2000-01-20 | Alterungsschutztetrapeptid, dieses enthaltende pharmazeutische zusammensetzungen und seine verwendung |
| EP00905499A EP1179008B1 (en) | 1999-05-11 | 2000-01-20 | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| CA002373128A CA2373128C (en) | 1999-05-11 | 2000-01-20 | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| ES00905499T ES2259998T3 (es) | 1999-05-11 | 2000-01-20 | Un tetrapeptido que demuestra el efecto gerontoprotector, sustancia farmacologica a base de el metodo de su utilizacion. |
| JP2000616229A JP3902406B2 (ja) | 1999-05-11 | 2000-01-20 | 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法 |
| US09/959,852 US6727227B1 (en) | 1999-05-11 | 2000-01-20 | Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| PCT/RU2000/000012 WO2000068255A2 (en) | 1999-05-11 | 2000-01-20 | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| DE60026826T DE60026826T2 (de) | 1999-05-11 | 2000-01-20 | Alterungsschutztetrapeptid, dieses enthaltende pharmazeutische zusammensetzungen und seine verwendung |
| AU27034/00A AU769847C (en) | 1999-05-11 | 2000-01-20 | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| IL14643200A IL146432A0 (en) | 1999-05-11 | 2000-01-20 | A tetrapeptide and a pharmaceutical composition containing the same |
| IL146432A IL146432A (en) | 1999-05-11 | 2001-11-11 | Tetrapeptide and pharmaceuticalcomposition containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99108841/14A RU2157233C1 (ru) | 1999-05-11 | 1999-05-11 | Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2157233C1 true RU2157233C1 (ru) | 2000-10-10 |
Family
ID=20219149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU99108841/14A RU2157233C1 (ru) | 1999-05-11 | 1999-05-11 | Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6727227B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1179008B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP3902406B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE321068T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU769847C (cg-RX-API-DMAC10.html) |
| CA (1) | CA2373128C (cg-RX-API-DMAC10.html) |
| DE (1) | DE60026826T2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2259998T3 (cg-RX-API-DMAC10.html) |
| IL (2) | IL146432A0 (cg-RX-API-DMAC10.html) |
| RU (1) | RU2157233C1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2000068255A2 (cg-RX-API-DMAC10.html) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2255757C1 (ru) * | 2004-06-22 | 2005-07-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Пептидное соединение, восстанавливающее функцию органов дыхания |
| RU2255756C1 (ru) * | 2004-06-22 | 2005-07-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Пептидное соединение, восстанавливающее функцию миокарда |
| RU2257910C1 (ru) * | 2003-12-25 | 2005-08-10 | Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) | Растительные экстракты, обладающие геропротекторной активностью и средство на их основе |
| RU2257909C1 (ru) * | 2003-12-25 | 2005-08-10 | Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) | Концентрат побегов черники и композиции на его основе, обладающие геропротекторной активностью |
| RU2297215C2 (ru) * | 2005-02-21 | 2007-04-20 | Государственное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет им. акад. И.П. Павлова" МЗ РФ | Антиоксидантное средство для лечения катаракты |
| EA010575B1 (ru) * | 2006-05-30 | 2008-10-30 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, обладающий иммуногеропротекторным действием, фармацевтическая композиция на его основе и способ ее применения |
| RU2464816C1 (ru) * | 2011-04-14 | 2012-10-27 | Общество с ограниченной ответственностью "Вилави" | Композиция биологически активных веществ, обладающая геропротекторной активностью, и способ комплексной коррекции возрастных изменений гормонального баланса, функций эпифиза и антиоксидантного статуса, включающий введение указанной композиции |
| RU2751945C2 (ru) * | 2015-05-22 | 2021-07-21 | Зе А2 Милк Компани Лимитед | Бета-казеин а2 и антиоксидантная способность |
| RU2829134C1 (ru) * | 2023-12-31 | 2024-10-24 | Дмитрий Петрович Елизаров | Биологически активная добавка, фармацевтически приемлемый носитель, содержащий биологически активную добавку, и способ применения биологически активной добавки |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
| EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
| US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| US7576174B2 (en) * | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| RU2161501C1 (ru) * | 2000-06-29 | 2001-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Способ получения пептидов, обладающих тканеспецифической активностью, и фармацевтические композиции на их основе |
| WO2002090380A1 (en) * | 2001-04-17 | 2002-11-14 | Sankt-Peterburgskaya Obschestvennaya Organizatsiya 'institut Bioregulyatsii I Gerontologii Czo Ramn' | Tetrapeptide stimulating the retinal function and the method of its application |
| US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
| US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
| US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
| US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
| US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
| WO2007004869A2 (en) * | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
| EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| RU2304444C1 (ru) * | 2006-05-23 | 2007-08-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения |
| RU2295970C1 (ru) * | 2006-05-23 | 2007-03-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения |
| RU2301678C1 (ru) * | 2006-05-30 | 2007-06-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения |
| DK2120991T3 (da) * | 2007-02-12 | 2014-04-28 | Biotempt Bv | Behandling af traumatisk blødning med korte oligopeptider |
| EP4135741A4 (en) * | 2020-04-15 | 2024-05-22 | Lactocore, Inc. | SYNTHETIC PEPTIDES FOR MODULATION OF METABOTROPIC GLUTAMATE RECEPTOR 5 |
| KR102841388B1 (ko) * | 2022-08-30 | 2025-08-01 | 주식회사 제이포셀 | 항노화 펩타이드 및 황기 추출물을 포함하는 항노화 화장료 조성물 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691203A (en) * | 1993-06-14 | 1997-11-25 | Kurashiki Boseki Kabushiki Kaisha | Method for serum-free culture of human vascular endothelial cells |
| RU2099078C1 (ru) * | 1994-12-08 | 1997-12-20 | Акционерное общество закрытого типа "КОМКОН" | Средство, обладающее антистрессовым, стресспротекторным, ноотропным, антиалкогольным и антинаркотическим действием, способы профилактики и лечения с его использованием |
| RU2112512C1 (ru) * | 1995-09-22 | 1998-06-10 | Иванов Евгений Васильевич | Биологичеcки активная пищевая добавка "глутапирон", обладающая антиканцерогенным и геропротекторным действием |
| WO1998043686A1 (en) * | 1997-04-03 | 1998-10-08 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0851980A (ja) * | 1994-08-11 | 1996-02-27 | Asahi Glass Co Ltd | 合成遺伝子およびこれを用いた癌転移阻害活性を有するペプチドの製造方法 |
-
1999
- 1999-05-11 RU RU99108841/14A patent/RU2157233C1/ru not_active IP Right Cessation
-
2000
- 2000-01-20 JP JP2000616229A patent/JP3902406B2/ja not_active Expired - Fee Related
- 2000-01-20 CA CA002373128A patent/CA2373128C/en not_active Expired - Fee Related
- 2000-01-20 DE DE60026826T patent/DE60026826T2/de not_active Expired - Lifetime
- 2000-01-20 AT AT00905499T patent/ATE321068T1/de active
- 2000-01-20 IL IL14643200A patent/IL146432A0/xx active IP Right Grant
- 2000-01-20 ES ES00905499T patent/ES2259998T3/es not_active Expired - Lifetime
- 2000-01-20 AU AU27034/00A patent/AU769847C/en not_active Ceased
- 2000-01-20 WO PCT/RU2000/000012 patent/WO2000068255A2/en not_active Ceased
- 2000-01-20 EP EP00905499A patent/EP1179008B1/en not_active Expired - Lifetime
- 2000-01-20 US US09/959,852 patent/US6727227B1/en not_active Expired - Fee Related
-
2001
- 2001-11-11 IL IL146432A patent/IL146432A/en not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691203A (en) * | 1993-06-14 | 1997-11-25 | Kurashiki Boseki Kabushiki Kaisha | Method for serum-free culture of human vascular endothelial cells |
| RU2099078C1 (ru) * | 1994-12-08 | 1997-12-20 | Акционерное общество закрытого типа "КОМКОН" | Средство, обладающее антистрессовым, стресспротекторным, ноотропным, антиалкогольным и антинаркотическим действием, способы профилактики и лечения с его использованием |
| RU2112512C1 (ru) * | 1995-09-22 | 1998-06-10 | Иванов Евгений Васильевич | Биологичеcки активная пищевая добавка "глутапирон", обладающая антиканцерогенным и геропротекторным действием |
| WO1998043686A1 (en) * | 1997-04-03 | 1998-10-08 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
Non-Patent Citations (1)
| Title |
|---|
| МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Медицина, 1993, ч. 1, с. 375. * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2257910C1 (ru) * | 2003-12-25 | 2005-08-10 | Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) | Растительные экстракты, обладающие геропротекторной активностью и средство на их основе |
| RU2257909C1 (ru) * | 2003-12-25 | 2005-08-10 | Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) | Концентрат побегов черники и композиции на его основе, обладающие геропротекторной активностью |
| RU2255757C1 (ru) * | 2004-06-22 | 2005-07-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Пептидное соединение, восстанавливающее функцию органов дыхания |
| RU2255756C1 (ru) * | 2004-06-22 | 2005-07-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Пептидное соединение, восстанавливающее функцию миокарда |
| RU2297215C2 (ru) * | 2005-02-21 | 2007-04-20 | Государственное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет им. акад. И.П. Павлова" МЗ РФ | Антиоксидантное средство для лечения катаракты |
| EA010575B1 (ru) * | 2006-05-30 | 2008-10-30 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, обладающий иммуногеропротекторным действием, фармацевтическая композиция на его основе и способ ее применения |
| RU2464816C1 (ru) * | 2011-04-14 | 2012-10-27 | Общество с ограниченной ответственностью "Вилави" | Композиция биологически активных веществ, обладающая геропротекторной активностью, и способ комплексной коррекции возрастных изменений гормонального баланса, функций эпифиза и антиоксидантного статуса, включающий введение указанной композиции |
| RU2751945C2 (ru) * | 2015-05-22 | 2021-07-21 | Зе А2 Милк Компани Лимитед | Бета-казеин а2 и антиоксидантная способность |
| RU2751945C9 (ru) * | 2015-05-22 | 2021-12-21 | Зе А2 Милк Компани Лимитед | Бета-казеин а2 и антиоксидантная способность |
| RU2829134C1 (ru) * | 2023-12-31 | 2024-10-24 | Дмитрий Петрович Елизаров | Биологически активная добавка, фармацевтически приемлемый носитель, содержащий биологически активную добавку, и способ применения биологически активной добавки |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1179008A2 (en) | 2002-02-13 |
| ES2259998T3 (es) | 2006-11-01 |
| AU769847B2 (en) | 2004-02-05 |
| CA2373128C (en) | 2007-03-13 |
| ATE321068T1 (de) | 2006-04-15 |
| IL146432A (en) | 2007-06-03 |
| JP3902406B2 (ja) | 2007-04-04 |
| WO2000068255A3 (en) | 2001-06-14 |
| CA2373128A1 (en) | 2000-11-16 |
| AU2703400A (en) | 2000-11-21 |
| DE60026826T2 (de) | 2007-04-12 |
| JP2003526622A (ja) | 2003-09-09 |
| US6727227B1 (en) | 2004-04-27 |
| WO2000068255A2 (en) | 2000-11-16 |
| AU769847C (en) | 2005-02-17 |
| EP1179008B1 (en) | 2006-03-22 |
| DE60026826D1 (de) | 2006-05-11 |
| IL146432A0 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1179008B1 (en) | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application | |
| JP2810240B2 (ja) | サイトカイン調節剤およびサイトカインレベルの変化に関連する病状および状態における使用方法 | |
| Park et al. | The gubernaculum shows rhythmic contractility and active movement during testicular descent | |
| JP2020196762A (ja) | 熱傷及び二次性合併症の予防及び治療方法 | |
| RU2362579C1 (ru) | Фармацевтическая композиция на основе пептида, обладающего противоопухолевым действием | |
| JP2001503011A (ja) | ペプチドと、その合成方法と、それをベースにした医薬品 | |
| EA011092B1 (ru) | Пептид, обладающий стресс-протекторным действием, фармацевтическая композиция на его основе и способ ее применения | |
| RU2110275C1 (ru) | Способ получения пептида, обладающего анаболической активностью, стимулирующего увеличение массы тела, развитие эпидермального слоя и роста волосяного покрова | |
| FR2503149A1 (fr) | Esters de mercaptoacyl-carnitines, procede pour leur preparation et leurs utilisations therapeutiques, notamment dans le traitement des intoxications et des brulures et en tant qu'agents mucolytiques | |
| DE60105042T2 (de) | Tetrapeptid zur stimulation der funktionellen aktivität von hepatozyten und seine therapeutische anwendung | |
| RU2177802C1 (ru) | Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения | |
| RU2242241C1 (ru) | Тетрапептид, регулирующий уровень глюкозы при сахарном диабете, фармакологическое средство на его основе и способ его применения | |
| JP2002516271A (ja) | 精神機能障害、記憶損失を改善し、麻酔をかけた哺乳動物の麻酔回復時間を短縮するための組成物及び方法 | |
| RU2115660C1 (ru) | Пептиды, обладающие антистрессорным, противосудорожным и нейропротекторным действием | |
| Riley et al. | Effect of proline analogs on oxygen toxicity-induced pulmonary fibrosis in the rat | |
| US7625870B2 (en) | Peptide substance restoring respiratory organs function | |
| PT1042286E (pt) | Compostos imunomoduladores contendo grupos gama-glutamilo e beta-aspartilo e métodos para os preparar | |
| RU2367467C2 (ru) | Фармацевтическая композиция на основе пептида, нормализующего мочеиспускание, и способ ее применения | |
| US6248716B1 (en) | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide | |
| TWI863205B (zh) | 具傷口癒合功效之鱸魚胜肽及其組成物 | |
| JP7204758B2 (ja) | 糖尿病性足の場合における組織酸素化を増強するための医療用製剤とその使用 | |
| JP2000136137A (ja) | 虚血再潅流性脳障害軽減剤 | |
| HU196226B (en) | Process for producing new tripeptide derivatives of antiamnesic activity and pharmaceutical compositions containing them as active components | |
| HK1012551B (en) | Peptide, a method of obtaining it and a pharmaceutical compound based on it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| PC4A | Invention patent assignment |
Effective date: 20070125 |
|
| QB4A | Licence on use of patent |
Effective date: 20071003 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180512 |